These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32090517)

  • 21. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
    Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
    Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT Program.
    Wadden TA; Tsai AG; Tronieri JS
    Obesity (Silver Spring); 2019 Oct; 27(10):1562-1566. PubMed ID: 31544345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide: A New Option for the Treatment of Obesity.
    Nuffer WA; Trujillo JM
    Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
    O'Neil PM; Garvey WT; Gonzalez-Campoy JM; Mora P; Ortiz RV; Guerrero G; Claudius B; Pi-Sunyer X;
    Endocr Pract; 2016 Nov; 22(11):1277-1287. PubMed ID: 27482610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
    O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
    Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
    von Scholten BJ; Davies MJ; Persson F; Hansen TW; Madsbad S; Endahl L; Jepsen CH; Rossing P
    J Diabetes Complications; 2017 Jul; 31(7):1164-1168. PubMed ID: 28462892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
    Kolotkin RL; Gabriel Smolarz B; Meincke HH; Fujioka K
    Clin Obes; 2018 Feb; 8(1):1-10. PubMed ID: 29045079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.
    Suliman M; Buckley A; Al Tikriti A; Tan T; le Roux CW; Lessan N; Barakat M
    Diabetes Obes Metab; 2019 Jun; 21(6):1498-1501. PubMed ID: 30768836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
    Bensignor MO; Bramante CT; Bomberg EM; Fox CK; Hale PM; Kelly AS; Mamadi R; Prabhu N; Harder-Lauridsen NM; Gross AC
    Pediatr Obes; 2023 Sep; 18(9):e13061. PubMed ID: 37264767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Fujioka K; O'Neil PM; Davies M; Greenway F; C W Lau D; Claudius B; Skjøth TV; Bjørn Jensen C; P H Wilding J
    Obesity (Silver Spring); 2016 Nov; 24(11):2278-2288. PubMed ID: 27804269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
    Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
    BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.
    Simonds SE; Pryor JT; Koegler FH; Buch-Rasmussen AS; Kelly LE; Grove KL; Cowley MA
    Diabetes; 2019 Apr; 68(4):683-695. PubMed ID: 30674622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
    Jensen SBK; Janus C; Lundgren JR; Juhl CR; Sandsdal RM; Olsen LM; Andresen A; Borg SA; Jacobsen IC; Finlayson G; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    Nat Commun; 2022 Aug; 13(1):4770. PubMed ID: 35970829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.